Oncology

Biosimilar Savings Through 2025 Could Total $38.4 Billion

January 4th 2022

By Tony Hagen

Savings from adalimumab biosimilars, which won't enter the US market until 2023, account for a significant share of the total, investigators said.

Bevacizumab Biosimilar Candidate Demonstrates High Similarity to Avastin in NSCLC

January 3rd 2022

By Deana Ferreri, PhD

Article

Patients with stage IV nonsquamous non–small cell lung cancer (NSCLC) demonstrated equivalent outcomes when treated with MYL-1402O or Avastin.

Report: Biosimilar Competition in Europe

January 1st 2022

By Tony Hagen

Article

Biosimilars have produced more than $20 billion of savings in Europe, but more use of these agents is needed.

Highly Confident, Biosimilar Companies Notch Global Commercialization Deals

December 24th 2021

By Tony Hagen

Article

With fewer of the risks associated with novel drug development, biosimilar candidates allow manufacturers to plan far into the future for marketing needs.

In Canada, More Mandatory Switching

December 23rd 2021

By Tony Hagen

Article

In Canada, a new jurisdiction inaugurates mandatory switching to biosimilars.

2021 Was an "Inflection Year" for Biosimilars

December 21st 2021

By Tony Hagen

Article

The year 2021 brought several firsts in biosimilars and set the stage for expansion across therapeutic areas including diabetes and ophthalmology.

Panelists Discuss Regulatory Perspective on Biosimilars

December 20th 2021

By Tony Hagen

Article

A trio of regulatory experts discuss the current standing of biosimilar policy in the United States and expectations going forward.

Molecular Selection Boosts pCR Rate in Early Breast Cancer Trial

December 20th 2021

By Tony Hagen

Article

Investigators said pathologic complete response (pCR) improved in a trastuzumab biosimilar/pertuzumab trial when patients were preselected for a subtype of breast cancer.

Study: Data for Cross-Switching of Biosimilars Are Scarce but Supportive

December 16th 2021

By Tony Hagen

Article

Investigators said more evidence would help to convince clinicians of the safety of switching between biosimilar products.

Xbrane Seeks to Bring Keytruda and Darzalex Biosimilars to Market

December 15th 2021

By Tony Hagen

Article

Xbrane Biopharma of Stockholm, Sweden, said its next biosimilar candidates will target the demand for oncology and hematology therapeutics.